Tag: upadacitinib

AbbVie bags RINVOQ FDA approval for nr-axSpA in adults

businessnewstoday- October 22, 2022

RINVOQ FDA approval for nr-axSpA : AbbVie has bagged approval for its selective JAK inhibitor RINVOQ (upadacitinib 15 mg, once daily) from the US Food ... Read More

AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial

pharmanewsdaily- June 8, 2020

AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in ... Read More